Biovitrum: Invitation to Press and Analyst Meeting and Conference Call.Presentation of Year End Report STOCKHOLM, Sweden -- The biopharma company Biovitrum (STO:BVT BVT Bouvet Island (ISO Country code) BVT Brevet BVT Bournville Village Trust (UK) BVT Build Verification Test (Software testing process) ), invites media and analysts to a press- and analyst meeting in Stockholm and conference call on Friday February 23 in conjunction with the disclosure of the year end report for 2006. The report is scheduled for publication at 08:30 (CET CET abbr. Central European Time CET Central European Time CET n abbr (= Central European Time) → hora de Europa central CET abbr ) on the same date. The report will be presented by CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. Mats Pettersson and CFO See Chief Financial Officer. Goran Arvidson. Press and analyst meeting in Stockholm Time: Friday, February 23 at 11:00 (CET) Venue: IVA, Grev Turegatan 16, Stockholm, conference room "Rausing" Coffee will be served following the presentation. Please register not later than 16:00 (CET) on Wednesday February 21, 2006 by either sending e-mail to marianne.gripe gripe v. To have sharp pains in the bowels. n. 1. gripes Sharp, spasmodic pains in the bowels. 2. A firm hold; a grasp. @biovitrum.com or contacting Marianne Gripe at +46 8 697 3427. Conference Call Time: Friday, February 23 at 15:30 (CET) Dial-in: +46 8 506 269 30 A recorded version of the conference call will be available for seven days on phone no: +46 8 506 269 49 access code: 161831# The slide presentation from both the conferences will be available on www.biovitrum.com / investor relations/ presentations. About Biovitrum Biovitrum is one of the largest biopharma companies in Europe. With operations in Sweden and in the UK Biovitrum conducts research and develops pharmaceuticals for unmet medical needs both for common diseases and conditions that affect smaller patient populations. Biovitrum has a broad and balanced R&D portfolio with several projects in clinical and preclinical phases for the treatment of obesity, diabetes, inflammation and eye and blood diseases as well as a number of well defined niche indications. Biovitrum develops and produces protein-based drugs on a contractual basis and markets a range of specialist pharmaceuticals primarily in the Nordic countries. Biovitrum has revenues of approximately SEK SEK In currencies, this is the abbreviation for the Swedish Krona. Notes: The currency market, also known as the Foreign Exchange market, is the largest financial market in the world, with a daily average volume of over US $1 trillion. 1.2 billion and 550 employees. Biovitrum is listed on the Stockholm Stock Exchange The Stockholm Stock Exchange (Swedish: Stockholmsbörsen) is a stock exchange located in Stockholm, Sweden. Founded in 1863 [1] it is the primary securities exchange of the Nordic Countries. since September 15, 2006. For more information see www.biovitrum.com/. This information was brought to you by Waymaker http://www.waymaker.net |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion